Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Protein Kinases. Found 16 abstracts

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DP, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Feb 22;378(8):731-9.
Vijayan RS, He P, Modi V, Duong-Ly KC, Ma HC, Peterson JR, Dunbrack RL, Levy RM. Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors. Journal of medicinal chemistry. 2015 Jan;58(1):466-79.   PMCID: 4326797
Huang H, Yen TJ. BubR1 is an effector of multiple mitotic kinases that specifies kinetochore: microtubule attachments and checkpoint. Cell cycle (Georgetown, Tex). 2009 Apr 15;8(8):1164-7.
Enders GH. Expanded roles for Chk1 in genome maintenance. The Journal of biological chemistry. 2008 Jun 27;283(26):17749-52.   PMCID: PMC2440615
Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-S20; quiz S21-S22.
Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. The Journal of investigative dermatology. 2008 Apr;128(4):980-7.
Yeager N, Brewer C, Cai KQ, Xu XX, Di Cristofano A. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res. 2008 Jan 15;68(2):444-9.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Robb VA, Astrinidis A, Henske EP. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.[erratum appears in Mod Pathol. 2006 Jun;19(6):889]. Modern Pathology. 2006 Jun;19(6):839-46.
Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004 Jul 29;23(34):5853-7.
Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med. 2004 May;10(5):484-6.
Hoffman DB, Pearson CG, Yen TJ, Howell BJ, Salmon ED. Microtubule-dependent changes in assembly of microtubule motor proteins and mitotic spindle checkpoint proteins at PtK1 kinetochores. Mol Biol Cell. 2001 Jul;12(7):1995-2009.
Sudakin V, Chan GK, Yen TJ. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol. 2001 Sep 03;154(5):925-36.
Chan GK, Jablonski SA, Sudakin V, Hittle JC, Yen TJ. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J Cell Biol. 1999 Sep 06;146(5):941-54.
Chan GK, Schaar BT, Yen TJ. Characterization of the kinetochore binding domain of CENP-E reveals interactions with the kinetochore proteins CENP-F and hBUBR1. J Cell Biol. 1998 Oct 05;143(1):49-63.
Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991 Oct 11;254(5029):274-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Protein Kinases

Protein Kinases metabolism genetics drug effects Protein Kinase Inhibitors Kinetochores physiology Non-US Gov't Support pharmacology Sirolimus US Gov't Support-PHS Human Signal Transduction Mice Phosphorylation chemistry pathology Apoptosis Female Hela Cells pa [Pathology] Non-Histone Chromosomal Proteins EC 2-7-1-37 (Protein Kinases) Protein-Serine-Threonine Kinases Mitotic Spindle Apparatus Amino Acid Sequence Cell Proliferation Mitosis Neoplasms EC 2-7-1 (mTOR protein) antagonists & inhibitors 1-Phosphatidylinositol 3-Kinase EC 2-7-1-137 (1-Phosphatidylinositol 3-Kinase) Recombinant Fusion Proteins Nocodazole therapeutic use DNA Mutational Analysis Proteins Tumor Cell Line ultrastructure Gene Expression Transgenic Mice Antineoplastic Agents Microtubules Aged Middle Aged 53123-88-9 (Sirolimus) drug therapy Cell Cycle Proteins me [Metabolism] Molecular Sequence Data Male Animal Ribosomal Protein S6 analogs & derivatives Protein Binding dt [Drug Therapy] Metaphase Ligases Calcium-Binding Proteins Proto-Oncogene Proteins Reporter Genes Adult enzymology Cell Cycle Molecular Cloning Anaphase Protein Conformation Pyrazoles EC 2-7-1-37 (Protein-Serine-Threonine Kinases) an [Analysis] Hematologic Diseases Enzyme Activation Melanoma Morpholines Proto-Oncogene Proteins B-raf Immunoenzyme Techniques Skin Neoplasms Interferon-alpha 0 (Proto-Oncogene Proteins) Gene Expression Regulation mo [Mortality] Lymphangioleiomyomatosis Survival Analysis K562 Cells Rats Biocatalysis Mink Neoplasm) 0 (DNA 0 (Neuropeptides) Cisplatin 80 and over Aged Nevus Molecular Models aa [Analogs & Derivatives] Non-US Gov't Research Support Amino Acid Motifs Preschool Child Proto-Oncogene Proteins p21(ras) 0 (Chromones) Cell Line Small Molecule Libraries Infant Cocarcinogenesis Binding Sites ae [Adverse Effects] Clinical Trials as Topic Human Chromosomes Proportional Hazards Models ai [Antagonists & Inhibitors] Oncogenic Retroviridae Proteins 0 (cci 779) Oncogenes Young Adult US Gov't Research Support-PHS Biological Models Macromolecular Systems human) 0 (RHEB protein Paclitaxel ras Proteins therapy Protein Databases etiology Monomeric GTP-Binding Proteins 0 (Morpholines) biosynthesis Cultured Cells Neuropeptides myc Genes EC 3-6-5-2 (Monomeric GTP-Binding Proteins) Xenopus Eukaryotic Initiation Factor-4E Allosteric Regulation Cell Division Allosteric Site ci [Chemically Induced] Practice Guidelines as Topic cdc Genes Dynein ATPase Thyroid Gland Kidney Neoplasms Oncogene Protein v-akt Oligodeoxyribonucleotides EC 2-7-1-37 (proto-oncogene protein akt) Adolescent Multiple Primary Neoplasms Follicular Adenocarcinoma Prognosis Cultured Tumor Cells 0 (Interferon-alpha)
Last updated on Friday, March 02, 2018